SCHEMBL3497097

SCHEMBL3497097

CC1(C)CC(Nc2nc(Nc3ccc4c(c3)OC(C)(C)C(=O)N4CCF)ncc2C#N)CC(C)(C)N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 2/20 0.37
PTK2 Q05397 3/20 0.37
PTK2B Q14289 1/20 0.37
SLC2A1 P11166 2/20 0.36
PRKCD Q05655 1/20 0.36
FLT3 P36888 3/20 0.36
CHEK1 O14757 1/20 0.36
LRRK2 Q5S007 5/20 0.36
KDR P35968 2/20 0.36
AURKA O14965 2/20 0.36
RET P07949 2/20 0.36
MAPK8 P45983 2/20 0.36
MAPK9 P45984 2/20 0.36
MST1R Q04912 2/20 0.36
BTK Q06187 2/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496173 0.93 LRRK2 (0.41) PRKCQPTK2PTK2BSLC2A1PRKCD
SCHEMBL3495251 0.92 PRKCQ (0.37) PRKCQPTK2PTK2BSLC2A1PRKCD
SCHEMBL1741179 0.89 SYK (0.45) PRKCQPTK2PTK2BPRKCDFLT3
SCHEMBL3496532 0.89 SYK (0.41) PRKCQPTK2PTK2BSLC2A1PRKCD
SCHEMBL3495540 0.88 PRKCQ (0.37) PRKCQPTK2PTK2BSLC2A1PRKCD
SCHEMBL3495162 0.87 PTK2 (0.36) PRKCQPTK2PTK2BSLC2A1PRKCD
SCHEMBL3496014 0.85 LRRK2 (0.40) PRKCQPTK2PTK2BSLC2A1PRKCD
SCHEMBL3495592 0.82 PRKCQ (0.36) PRKCQPTK2PTK2BSLC2A1PRKCD
SCHEMBL3496340 0.81 PRKCQ (0.47) PRKCQPTK2PTK2BPRKCDFLT3
SCHEMBL3496087 0.81 SYK (0.41) PRKCQPTK2PTK2BSLC2A1PRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885PTK2 513/4885PTK2B 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.